National Healthcare Security Administration: More than 180 new technologies and products have been added to the price list, exploring the establishment of a system for pre-approval of medical service prices.

Today, Dong Zhaohui, Deputy Director of the Price Bidding Department of the National Medical Insurance Administration, stated at the "Price Approval Benefits People's Livelihood" media briefing that the National Medical Insurance Administration clearly supports clinical innovative technologies and continues to promote the rapid entry of high-level new technologies and products into clinical practice and achieve scale application. During the preparation of the approval guidelines, they have continuously tracked the innovation dynamics of the medical industry, focused on filling the gaps in diagnosis and treatment, represented innovative projects at the forefront of technology, and have added more than 180 new technology and product price projects, covering areas such as surgical robots, remote surgery, and proton therapy. The related price approval is seen as a key link to bridge the gap between medical technology research and development and clinical application, which helps stabilize market return expectations for innovative companies. He also revealed that the National Medical Insurance Administration is exploring the establishment of a pre-approval system for medical service prices, providing price policy guidance in advance for new technologies and products entering the clinical trial stage, and promoting the completion of price approval for relevant projects as soon as they are approved to accelerate the market transformation of high-level innovation achievements and promote the high-quality development of medical technology.